Battistella, M <br/><br/>
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.  [electronic resource] 

 -  The British journal of dermatology  Aug 2016 
 - 325-33 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.14626  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor<br/>Female<br/>Humans<br/>Ki-1 Antigen--metabolism<br/>Killer Cells, Natural--physiology<br/>Leukocytes, Mononuclear--metabolism<br/>Lymphoma, Large-Cell, Anaplastic--drug therapy<br/>Male<br/>Middle Aged<br/>Receptors, KIR2DL2--antagonists & inhibitors<br/>Skin--metabolism<br/>Skin Neoplasms--drug therapy<br/>Tumor Cells, Cultured<br/>Young Adult